Ameritas Advisory Services LLC Raises Holdings in Gilead Sciences, Inc. $GILD

Ameritas Advisory Services LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,492 shares of the biopharmaceutical company’s stock after buying an additional 616 shares during the quarter. Ameritas Advisory Services LLC’s holdings in Gilead Sciences were worth $609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hilltop National Bank purchased a new position in Gilead Sciences in the second quarter worth $86,000. Triad Wealth Partners LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $205,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Gilead Sciences by 8.2% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 556,766 shares of the biopharmaceutical company’s stock valued at $61,729,000 after purchasing an additional 42,128 shares during the period. Cornell Pochily Investment Advisors Inc. boosted its holdings in Gilead Sciences by 24.8% during the second quarter. Cornell Pochily Investment Advisors Inc. now owns 11,812 shares of the biopharmaceutical company’s stock worth $1,310,000 after buying an additional 2,349 shares in the last quarter. Finally, J2 Capital Management Inc grew its position in Gilead Sciences by 58.9% during the second quarter. J2 Capital Management Inc now owns 3,864 shares of the biopharmaceutical company’s stock worth $428,000 after buying an additional 1,432 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several research reports. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a report on Friday, July 25th. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. Finally, Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Gilead Sciences Stock Up 1.9%

Shares of Gilead Sciences stock opened at $112.69 on Monday. The company has a fifty day moving average price of $114.34 and a 200 day moving average price of $109.97. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a twelve month low of $83.98 and a twelve month high of $121.83. The stock has a market cap of $139.83 billion, a price-to-earnings ratio of 22.45, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the previous year, the firm posted $2.01 earnings per share. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at $978,880.80. This represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.